Battling cancer is the stock in trade of Seattle Genetics. From its headquarters in Bothell, Washington the biotechnology company has been developing innovative antibody based cancer treatments since 1998. Today they are the industry leader in the creation and commercialization of antibody drug conjugates or ADC. The technology harnesses the ability of monoclonal antibodies to target and deliver agents to kill cancer cells. Some of the strengths of the treatment is that it doesn’t damage the healthy cells, enhances anti-tumor activity and eliminates the toxic effects normally associated with chemotherapy.
Seattle Genetics also partners with a number of companies to give people around the world access to their groundbreaking therapies. Currently the ADC treatment they have developed is used in 60 countries. Some of the companies with which they have collaborated to market their antibody-based therapies include Takeda Pharmaceutical Company, Pfizer, Genentech, GlaxoSmithKline and AbbVie. This is important because their ADC therapy is one of the first new cancer treatments in over 30 years. Seattle Genetics also has a number of very promising therapies in their product pipeline
Dr. Clay Siegall, Co-Founder, CEO, and President of Seattle Genetics, has played a very important role in the company’s amazing growth. An innovative scientist long focused on rigorous research combined with drug development and testing, he built the company on scientific innovation. He also secured $1.2 billion in financing and FDA approval for ADCETRIS, their proprietary ADC product. Dr. Clay Siegall has been involved in cancer research for many years. Before co-founding Seattle Genetics, he worked with the National Institutes of Health, the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute.
After earning a University of Maryland undergrad degree in Zoology and a Genetics doctorate from George Washington University, he’s had his work published in more than 70 publications. He is a member of numerous biotech company boards and holds 15 patents. Dr. Siegall has also won several awards for his work on cancer research. At Seattle Genetics he leads a staff that includes over 800 employees that are passionate about trying to find new ways to help people living with cancer.
Learn more about Clay Siegall
http://www.ultragenyx.com/about/board/siegall/
http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf
